Theriva Biologics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Theriva Biologics generated cash of -$18,996,000, which is more than the previous year. Cash used in financing activities reached the amount of $625,000 last year. Net change in cash is therefore -$18,606,000.
Cash Flow
| 2014 | -16.07M | -48K | 19.02M |
|---|---|---|---|
| 2015 | -38.89M | -501K | 42.68M |
| 2016 | -27.90M | -569K | 26.70M |
| 2017 | -20.20M | -212K | 18.47M |
| 2018 | -17.27M | -7K | 29.08M |
| 2019 | -13.87M | 0 | 0 |
| 2020 | -12.16M | -9K | 3.35M |
| 2021 | -12.89M | -14K | 74.00M |
| 2022 | -19.08M | -4.39M | -1.93M |
| 2023 | -18.99M | -202K | 625K |
TOVX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 41.88M | 67.32M | 6.22M | 15.04M | 28.91M | 17.11M | 19.05M | 20.81M | 17.52M | 14.62M |
Operating activities | ||||||||||
Net income | -18.34M | -19.68M | -14.26M | -10.11M | -15.38M | -13.42M | -15.49M | -27.80M | -44.78M | -19.78M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 135K | 85K | 87K | 201K | 240K | 272K | 245K | 157K | 72K | 20K |
Stock-based compensation expense | 552K | 475K | 416K | 350K | 340K | 0 | 3.40M | 4.00M | 3.19M | 2.45M |
| Deferred income tax benefit | 552K | 475K | 416K | 350K | 340K | 0 | 3.40M | 4.00M | 3.19M | 2.45M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -157K | -385K | -363K | -1.42M | 1.28M | -987K | 27K | -2.42M | 3.41M | 854K |
Cash generated by operating activities | -18.99M | -19.08M | -12.89M | -12.16M | -13.87M | -17.27M | -20.20M | -27.90M | -38.89M | -16.07M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -417K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -202K | -116K | -14K | -9K | 0 | -7K | -212K | -569K | -501K | -48K |
Acquisitions Net | 0 | -4.28M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -202K | -4.39M | -14K | -9K | 0 | -7K | -212K | -569K | -501K | -48K |
Financing activities | ||||||||||
Common Stock Issued | 2.21M | 0 | 65.96M | 3.35M | 0 | 29.08M | 6.35M | 27.32M | 46M | 20.67M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -288K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -75K | -1.37M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 625K | -1.93M | 74.00M | 3.35M | 0 | 29.08M | 18.47M | 26.70M | 42.68M | 19.02M |
Net Change In Cash | -18.60M | -25.44M | 61.09M | -8.81M | -13.87M | 11.80M | -1.93M | -1.76M | 3.29M | 2.9M |
Cash at end of period | 23.27M | 41.88M | 67.32M | 6.22M | 15.04M | 28.91M | 17.11M | 19.05M | 20.81M | 17.52M |
| Data source | Data source |